Bordeaux University, INSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn), Cutaneous Lymphoma Oncogenesis Team, F-33000 Bordeaux, France; Saint Joseph University, Faculty of Medicine, Medical Genetics Unit (UGM), Beirut, Lebanon.
Saint Joseph University, Faculty of Medicine, Medical Genetics Unit (UGM), Beirut, Lebanon.
Blood Rev. 2021 Jul;48:100782. doi: 10.1016/j.blre.2020.100782. Epub 2020 Nov 17.
Lymphomas represent a heterogeneous group of cancers characterized by clonal lymphoproliferation. Over the past decades, frequent epigenetic dysregulations have been identified in hematologic malignancies including lymphomas. Many of these impairments occur in genes with established roles and well-known functions in the regulation and maintenance of the epigenome. In hematopoietic cells, these dysfunctions can result in abnormal DNA methylation, erroneous chromatin state and/or altered miRNA expression, affecting many different cellular functions. Nowadays, it is evident that epigenetic dysregulations in lymphoid neoplasms are mainly caused by genetic alterations in genes encoding for enzymes responsible for histone or chromatin modifications. We summarize herein the recent epigenetic modifiers findings in lymphomas. We focus also on the most commonly mutated epigenetic regulators and emphasize on actual epigenetic therapies.
淋巴瘤是一组以克隆性淋巴增生为特征的异质性癌症。在过去的几十年中，已在包括淋巴瘤在内的血液恶性肿瘤中鉴定出频繁的表观遗传失调。其中许多缺陷发生在具有既定作用且在调节和维持表观基因组方面具有公认功能的基因中。在造血细胞中，这些功能障碍可能导致异常的 DNA 甲基化、错误的染色质状态和/或改变的 miRNA 表达，从而影响许多不同的细胞功能。如今，显然淋巴肿瘤中的表观遗传失调主要是由编码组蛋白或染色质修饰酶的基因的遗传改变引起的。我们在此总结了淋巴瘤中最近的表观遗传修饰因子研究结果。我们还重点介绍了最常见的突变表观遗传调节剂，并强调了实际的表观遗传疗法。
